Privia Health Group, Inc.
NASDAQ:PRVAMedical - Healthcare Information Services
+$0.15 today
- Market cap
- $3.14B
- Beta
- 0.87
- P/E (TTM)
- 134.4
- EPS (TTM)
- $0.18
Volume 2.38M
Average 0.95M
PRVA Cash & Equivalents
Cash on hand and highly liquid investments that can be converted to cash almost immediately.
Privia Health Group, Inc.NASDAQ: PRVA
Cash & Equivalents · Q2 FY2026 · quarter ended Jun 2026
Cash & equivalents rises 5.7% from a year ago
Cash & equivalents stood at $412.2M at the end of Q2 FY2026, up 5.7% from a year earlier and down 1.7% from the prior quarter. Over 3 fiscal years it compounded at +11.3% a year.
Context
- Cash & equivalents amounted to 27.7% of total assets at the end of Q2 FY2026, down 3.0 pp from a year earlier.
- Cash & equivalents increased in 2 of the last 3 fiscal years.
What to watch
Whether cash & equivalents keeps rising in the next quarterly balance sheet after a +5.7% change from a year earlier.
Sources:Balance SheetText generated from reported figures; not investment advice.
Cash & Equivalents history
USD · from the balance sheet
- Latest · FY2025
- 479.69M USD
- Year-over-year change
- -2.3%
- 4-year CAGR
- +10.6%
| Period | Period end | Cash & Equivalents | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 479.69M | -2.3% |
| FY2024 | 2024-12-31 | 491.15M | +26.1% |
| FY2023 | 2023-12-31 | 389.51M | +11.9% |
| FY2022 | 2022-12-31 | 347.99M | +8.6% |
| FY2021 | 2021-12-31 | 320.58M | — |
Cash & Equivalents vs competitors
How PRVA compares with its peers on the latest reported figures
- PRVA's Jun 2026 cash & equivalents of $412.2M is the 3rd highest of the 10 companies compared; the peer median is $166.01M.
- Its year-over-year change of +5.7% is the 3rd highest of 10, against a peer median of -19.4%.
- Cash & equivalents amounts to 27.7% of total assets for PRVA, versus a peer median of 14.5%.
| Company | Period | Latest balance | YoY | 3-year CAGR | % of assets |
|---|---|---|---|---|---|
| Mar 2026 | $750.74M | -37.1% | -5.2% | 26.7% | |
| Mar 2026 | $478.38M | +85.0% | +14.2% | 20.3% | |
| Jun 2026 | $412.2M | +5.7% | +11.3% | 27.7% | |
| Mar 2026 | $211.77M | +256.5% | +9.7% | 69.9% | |
| Mar 2026 | $179.21M | -19.4% | -30.3% | 55.0% | |
| Mar 2026 | $166.01M | -32.7% | -6.9% | 8.8% | |
| Mar 2026 | $139.99M | +1.0% | -28.0% | 9.3% | |
| Apr 2026 | $74.71M | -17.8% | -25.2% | 11.2% | |
| Mar 2026 | $59.86M | -82.5% | -24.1% | 14.5% | |
| Mar 2026 | $3.85M | -43.4% | -36.7% | 4.4% | |
| Peer median (excluding PRVA) | $166.01M | -19.4% | -24.1% | 14.5% | |
Competitors are the stored peer set for PRVA. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Balance Sheet
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Cash & Equivalents | 320.58M | 347.99M | 389.51M | 491.15M | 479.69M |
| Short-term Investments | 0 | 0 | 0 | 0 | 0 |
| Net Receivables | 117.4M | 189.6M | 290.77M | 316.18M | 400.9M |
| Inventory | 0 | 0 | 0 | 0 | 0 |
| Other Current Assets | 0 | 14.37M | 20.53M | 27.5M | 30.41M |
| Total Current Assets | 446.68M | 551.96M | 700.8M | 834.82M | 911M |
| Property, Plant & Equipment (Net) | 14.14M | 11.48M | 8.94M | 6.07M | 9.3M |
| Goodwill | 127.94M | 126.94M | 138.75M | 141.62M | 209.84M |
| Intangible Assets | 59.74M | 57.39M | 107.63M | 109.81M | 215.92M |
| Long-term Investments | 0 | 0 | 0 | 0 | 0 |
| Tax Assets | 33.36M | 40.37M | 35.2M | 26.38M | 2.27M |
| Other Non-current Assets | 4.52M | 4.68M | 8.58M | 17.09M | 21.04M |
| Total Non-current Assets | 239.7M | 240.85M | 299.1M | 300.96M | 458.38M |
| Total Assets | 686.37M | 792.81M | 999.9M | 1.14B | 1.37B |
| Account Payables | 2.97M | 6.73M | 7.88M | 9.76M | 7.97M |
| Short-term Debt | 875K | 0 | 0 | 0 | 0 |
| Tax Payables | 0 | 0 | 0 | 0 | 0 |
| Deferred Revenue | 0 | 0 | 0 | 0 | 0 |
| Other Current Liabilities | 148.2M | 214.6M | 332.05M | 370.61M | 503.07M |
| Total Current Liabilities | 190.46M | 264.27M | 386.95M | 449.15M | 568.52M |
| Long-term Debt | 31.69M | 0 | 0 | 0 | 0 |
| Deferred Tax Liabilities | 0 | 0 | 0 | 0 | 0 |
| Deferred Revenue (Non-current) | 0 | 0 | 0 | 0 | 0 |
| Other Non-current Liabilities | 3M | 1M | 313K | 153K | 2.58M |
| Total Non-current Liabilities | 45.73M | 9.49M | 5.56M | 3.19M | 9.92M |
| Total Liabilities | 236.19M | 273.76M | 392.51M | 452.34M | 578.44M |
| Common Stock | 1.08M | 1.15M | 1.18M | 1.2M | 1.24M |
| Retained Earnings | (208.11M) | (216.69M) | (193.61M) | (179.23M) | (156.31M) |
| Accumulated OCI | 0 | 0 | 0 | 0 | 0 |
| Other Stockholders Equity | 0 | 0 | 0 | 0 | 0 |
| Minority Interest | 23.31M | 19.96M | 45.95M | 48.26M | 53.73M |
| Total Equity | 450.18M | 519.05M | 607.39M | 683.45M | 790.94M |
| Total Debt | 46.5M | 11.5M | 8.29M | 5.59M | 9.53M |
| Net Debt | (274.08M) | (336.49M) | (381.22M) | (485.56M) | (470.15M) |
Privia Health Group, Inc.
NASDAQ:PRVA
Intrinsic Alpha fair value
Locked
Current Price
$24.60
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.